ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, in a recent cohort analysis in CML patients, it is reported that inhibition of the renin-angiotensin system (RAS) by ACE inhibitors or ARBs is associated with reduced arterial occlusive events in hypertensive CML patients treated with second or third generation BCR-ABL inhibitors (Mulas et al., 2020).